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Abstract
The study objective was to define the special features of the clinical course of knee joint osteoarthrosis depending on
6-sulfatoxymelatonin urinaryexcretion profile.
Materials and methods. We surveyed 141 patients with radiological Stage II-III osteoarthrosis (OA) of the knee joints (18
female subjects). Diagnosis of OA was established on the basis of ACR criteria (1991) and EULAR (2010) recommendations.
We determined the AO clinical indexes (Lequesne, WOMAC, KOOS), HAQ functional index, sleep quality and psycho-
emotional state indicators. ELISA was used to assess 6-sulfatoxymelatonin urinary excretion profile.
Results. It was established that 66% of patients with OA of knee joints had a reduced 6-sulfatoxymelatonin urinary excretion
compared to this of practically healthy individuals. AO patients with low 6-SMT urinary excretion profiles had higher incidence
of severe insomnia and depressive disorders. Reduction in 6-SMT excretion was associated with a moderate increase in pain
syndrome and deterioration of physical functions by Lequesne, WOMAC, KOOS, and HAQ indexes.
Conclusion. The reducedmelatonin production in OA patients is a factor of more severe clinical course of the disease due to
deterioration of the psycho-emotional state, the development of pain syndrome, and functional disorders.
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Problem statement and analysis of the
recent research
Osteoarthrosis (OA) is one of the most common chronic dis-
eases, closely associated with the aging process. According
to Framingham Osteoarthritis Study, radiologically confirmed
knee OA is diagnosed in 13.8% of adults over 26, in 19.2% of
patients over 45 years old, and in 37.4% of individuals over
60 [10]. Age is known as unmodified OA development factor
[16]. The mechanisms that precondition the osteoarthrosis-
like articular cartilage transformation are associated with in-
hibition of expression of clock-genes and disturbances of
circadian rhythms [20]. Aging is accompanied with certain in-
hibition of melatonin production - a key regulator of circadian
rhythms, antioxidant, cytoprotector, and neuromodulator [12,
18]. The deficiency of melatonin is considered a factor in the
development of age-associated neurodegenerative diseases,
insomnia, and metabolic disorders (obesity, type 2 diabetes)
[12]. It has been experimentally proved that melatonin has a
chondroprotective potential and may be involved in the OA
pathogenesis due to the effect on circadian rhythms of chon-
drocytes [17]. It is known that OA patients more often present
with sleep disturbances, depressive and cognitive impairment
than general population subjects [9, 19]. Meanwhile, the issue
of melatonin production disturbance and its association with
the clinical course of OA requires further study.
Study objective was to characterize the clinical course
of osteoarthrosis (OA) of the knee joints, depending on the
6-sulfatexymelatonin urinary excretion profile.
1. Materials and methods of the study
We surveyed 141 patients with radiological Stage II-III os-
teoarthrosis (OA) of knee joints (76.6% female) of the average
age 58.4 ± 7.91 years with a 10.5 ± 6.50-year history of the
disease. 47 (33.3%) patients had a combination of knee and
hip joint OA. Diagnosis of OA was established on the basis
of ACR 1991 criteria for knee and hip joints [5] and EULAR
(2010) recommendations [11].
The study was in line with the basic bioethical standards
of the Helsinki Declaration (1989), the Council of Europe
Convention on Human Rights and Biomedicine (1977), the
relevant provisions of the WHO, the International Code of
Medical Ethics (1983) and the laws of Ukraine.
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The criteria for randomization of patients in the study were
as follows: radiologically confirmed Stage II-III osteoarthrosis
(OA) of knee joints; age - 30-75; duration of the disease -
at least 1 year; and the consent to participate in the study.
The non-inclusion criteria were: the reluctance of a patient
to participate; oral administration of glucocorticoids; any
intra-articular manipulations (injections of glucocorticoids,
hyaluronic acid, etc.) during the last 4 weeks; endoprosthetics
of knee or hip joints; difficult and uncompensated states;
oncological diseases; pregnancy and lactation; alcohol and
drug addiction.
For the purposes of clinical evaluation of gonarthrosis
symptoms severity, Lequesnealgo-functional index [15], WOMAC
- Western Ontario and McMaster Universities Osteoarthritis In-
dex [22], and KOOS - Knee Injury and Osteoarthritis Outcome
Score [14] were determined. The disturbances of physical
functions were evaluated under the HAQ - Health Assess-
ment Questionnaire [8]. The insomnia was assessed using a
questionnaire for assessing night sleep [1] and Epworth (Day-
time) Sleepiness Scale [13]. The depressive disorders were
determined under the Beck Depression Inventory [6].
The production of melatonin was evaluated against a 6-
sulfatexymelatonin (6-SMT) urinary excretion profile, which
is considered a stable indicator, closely correlated with night
peak blood hormone levels [21]. The 6-sulfatexymelatonin
(6-SMT) concentration was determined using ELISA method
and 6-sulfatoxymelatonin ELISA Kit (Buhlmann, Sweden).
6-SMT concentration was measured in two portions of urine
collected from 18:00 to 22:00 and from 22:00 to 6:00, reflect-
ing production of melatonin in daytime and at night. The
average rate of 6-SMT excretion per 1 mg of creatinine was
calculated. To establish reference intervals, 36 practically
healthy individuals (72.2% - women) from the control group
aged 57.1±9.95 (M ± SD) were surveyed.
The results obtained were statistically processed using
computer programs MS Excel, IBM Statistics SPSS 22, and
STATISTICA 6.0. The reliability of the results was assessed
by Student‘s t-test (with parametric data distribution) and
Mann-Whitney U-test (with nonparametric data distribution).
The normality of distribution was determined using the Shapiro-
Wilk test. The percentile analysis was used to determine the
median, percentiles, and a 95% confidence interval (CI). The
relationship between the indicators was estimated against
Pearson’s correlation coefficient. The odds ratio (OR) was
determined. Differences by the frequency of signs were deter-
mined by Fisher’s exact test. The differences were considered
statistically significant with p <0.05.
2. Study results
It was found that practically healthy individuals from the con-
trol group had the 6-SMT urinary excretion level ranging from
13.7 to 31 ng/mg creatinine (95% CI) with a median and in-
terquarantine interval of 25.0 ng/mg creatinine [19.4; 28.3].
The OA patients presented with the 6-SMT excretion ranging
from 10.6 to 24.3 ng/mg creatinine (95% CI) with median
and interquartile interval 16.1 ng/ml [12.7; 20.6], which was
significantly higher than those in the control group (Mann-
Whitney U-test, Z = 5.977, p <0.001). The OA patients were
divided into three groups according to the 6-SMT excretion
profile: Group 1 (n=48) included persons with a conditionally
normal indicator level > 19.4 ng/mg creatinine (over 25-th
percentile of the control group), Group 2 (n = 42) -with a
marginally-decreased 6-SMT level -13.7-19.4 ng/mg creati-
nine (from 5-th to 25-th percentile of the control group), and
Group 3 (n = 51) - with a low level of 6-SMT -<13.7 ng/mg
creatinine (below the 5-th percentile of the control group).
Thus, aberrant 6-SMT levels were found in 66% of patients
with OA, including 36.2% of those with lower levels, which
was 6.46 times higher than in the control group (p <0.001).
The analysis of clinical and demographic pattern showed
that the decrease in the 6-SMT excretion level was associated
with an increase in the age of patients, perhaps without evi-
dent gender differences (Table 1). The average age of patients
with aberrant 6-SMT profiles was higher (by 10.3 and 12.6%)
than in patients with normal 6-SMT excretion. Groups of
OA patients with normal and aberrant 6-SMT excretion did
not differ significantly in the mean duration of the disease.
However, patients with a low 6-SMT levels (<13.7 ng/mg cre-
atinine) presented with radiological stage III OA (3.4 times)
and combined lesion of knee and hip joints (2.5 times) statis-
tically significantly more often than the patients with normal
level of 6-SMT excretion.
In OA patients, the reduction in 6-SMT excretion was as-
sociated with an increase in the severity of clinical symptoms
of gonarthrosis, functional impairment, and a drop in quality
of life by Lequesne, WOMAC, KOOS, and HAQ indexes
(Table 2). The most significant differences in the above pa-
rameters were observed between patients with normal and low
levels of 6-SMT excretion, whereas patients with a marginally
low 6-SMT excretion had exaggeration of clinical symptoms
that was not statistically significant.
For example, OA patients with a 6-SMT excretion level
<13.7 ng/mg creatinine had Lequesne and HAQ indexes sta-
tistically significantly higher than patients with a 6-SMT ex-
cretion > 19.4 ng/mg creatinine (p <0.01) by 17.6% and
18.6%, respectively. Reduction of 6-SMT excretion in OA
patients was associated with an increase in the severity of
pain syndrome, stiffness and decreased physical activity un-
der WOMAC index. In patients with a level of 6-SMT <13.7
ng/mg creatinine, the pain, stiffness, physical activity and
total WOMAC scores were higher by 26.9; 22.4; 29.2 and
26.1%, respectively, than in patients with a level of 6 SMT
excretion > 19.4 ng/mg creatinine (p <0.01). Patients with
6-SMT excretion <13.7 ng/mg creatinine had WOMAC pain
score 14.6% higher than patients with 6-SMT excretion 13.7-
19.4 ng/mg creatinine (p <0.05). The analysis of KOOS
index confirmed that OA patients with a low level of 6-SMT
excretion had growing pain syndrome, lower functional per-
formance, and deteriorating quality of life. Patients with 6
SMT <13.7 ng/mg creatinine had scores of pain, symptoms,
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Table 1. Clinical and demographic pattern for patients with OA, ranked against the 6-sulfatexymelatonin urinary excretion
profile
Description
Patient groups by 6-SMT excretion level (ng/mg creatinine)
>19.4 13.7-19.4 <13.7
1 (n=48) 2 (n=42) 3 (n=51)
Men n (%) 11 (22.9%) 13 (31%) 9 (17.6%)
Women n (%) 37 (77.1%) 29 (69%) 42 (82.4%)
Age, years M±σ 54.1±7.51 59.7±6.79* 61.3±7.53*
OA history, years M±σ 8.81±6.29 11.1±6.41 10.8±6.33
Gonarthrosis n (%) 40 (83.3%) 24 (57.1%)* 30 (58.8%)*
Gonarthrosis + coxarthrosis n (%) 8 (16.7%) 18 (42.9%)* 21(41.2%)*
Radiological Stage II n (%) 38 (79.2%) 31 (73.8%) 15 (29.4%)**#
Radiological Stage III n (%) 10 (20.8%) 11 (26.2%) 36 (70.6%)**#
Notes:
1. * - statistically significant differences compared to Group 1 (*- p<0.05; **- p<0.01);
2. # - statistically significant differences compared to Group 2 (# - p<0.05).
Table 2. Lequesne, HAQ, WOMAC and KOOS indexes in OA patients depending on 6-sulfatexymelatonin urinary excretion
profile (M±SD)
Description Patient groups by 6-SMT profile (ng/mg creatinine)
>19.4 13.7-19.4 <13.7
1 (n=48) 2 (n=42) 3 (n=51)
Lequesne Index score 14.8±3.97 16.0±3.89 17.4±4.47**
HAQ score 1.18±0.38 1.28±0.31 1.40±0.36**
WOMAC score
Pain 44.5±15.2 49.2±16.2 56.5±14.5 *** / #
Symptoms + stiffness 49.5±19.0 55.5±22.0 60.6±18.3**
Physical activity 44.8±16.6 52.0±21.7 57.9±16.7 **
Total WOMAC 46.3±14.9 52.3±18.2 58.4±15.0 ***
KOOS score
Pain 48.1±9.90 45.8±13.4 41.6±10.1**
Symptoms 54.7±14.3 49.7±16.6 46.4±13.4*
Function (everyday life) 53.0±12.1 50.3±15.5 46.3±12.3*
Function (sports) 30.7±12.9 30.5±13.2 24.6±11.7 */#
QoL 45.2±11.2 44.5±15.0 39.8±12.0 *
Notes:
1. * - statistically significant differences compared to Group 1 (* - p<0.05; **- p<0.01; *** - p<0.001);
2. # - statistically significant differences compared to Group 2 (# - p<0.05).
”everyday life” functions, ”sport, active rest”, and quality of
life by KOOS lower by 13.5; 15.2; 12.6; 19.9 and 11.9%,
respectively, than patients with a level of 6-SMT excretion >
19.4 ng/mg creatinine (p <0.05).
Subjects with high (> 50 points) WOMAC index (Figure
1) and low (<50 points) KOOS index (Figure 2) dominated
among patients with low levels of 6-SMT excretion. Among
OA patients with 6-SMT level <13.7 ng/mg creatinine, the
proportion of subjects with total WOMAC > 50 points was
1.65 and 1.44 times higher than in patients with 6-SMT level
>19.4 ng/mg creatinine and 13.7-19.4 ng/mg creatinine, re-
spectively. Among patients with 6-SMT <13.7 ng/mg creati-
nine, the proportion of subjects with pain and KOOS scores
<50 points was lower 1.48 and 1.72 times than those among
patients with 6-SMT level > 19.4 ng/mg creatinine. OA pa-
tients with aberrant 6-SMT levels had twice as higher chances
of the total WOMAC growth (> 50 points) (OR - 2.13; 95%
CI - 1.05-4.30) than the patients with normal 6-SMT levels.
Sleep disturbances and changes in the psycho-emotional
state, including depression, are known as causes of the quality
of life deterioration in OA patients. According to the question-
naire on the assessment of sleep quality in the general group
of OA patients, 34 (24.1%) subjects without insomnia were
found (score> 21 points), 26 (18.4%) subjects presented with
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Figure 1. Frequency of severe manifestations of the disease by WOMAC index in OA patients depending on 6-SMT excretion
(ng/mg creatinine).
Notes:
* - p<0.05 compared to Group 1;
# - p<0.05 compared to Group 2 (Fisher’s exact test).
Figure 2. Frequency of severe manifestations of the disease by KOOS index in OA patients depending on 6-SMT excretion
(ng/mg creatinine).
Notes:
* - p<0.05 compared to Group 1;
# - p<0.05 compared to Group 2 (Fisher’s exact test).
marginal sleep disorders (19-21 points), and 81 (57.4%) - with
a pronounced insomnia (<19 points). Also, 42 (29.8%) sub-
jects without daytime sleepiness (Epworth scale ≤ 5 points)
were found among OA patients, while 38 (27.0%) had in-
significant drowsiness in the daytime (6-10 points), and 61
(43.3%) had an elevated need for sleep (<19 points). Among
the surveyed patients, 48 (34.0%) subjects did not present any
signs of depression (Beck Depression Inventory ≤ 13 points),
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52 (36.9%) had signs of mild depression (14-19 points), and
29.1% (41) - moderate depression (> 19 points). Patients
with clinical depression (≥ 29 points of the Beck Depression
Inventory) were not included in the study.
Among patients with low 6-SMT profile, the proportion
of people with insomnia exceeded that among patients with
normal and marginally lowered rates 2.27 and 1.47 times,
respectively (Table 3). With a decrease of 6-SMT excre-
tion <13.7 ng/mg creatinine, OA patients had much higher
chances of nocturnal insomnia (OR - 7.8; 95% CI - 3.01-18.6)
and daytime drowsiness (OR - 2.68; 95% CI - 1.18-6.10)
compared to patients with a level of 6-SMT > 19.4 ng/mg
creatinine. Moreover, OA patients with a low 6-SMT excre-
tion, had higher incidence of depressive disorders (OR - 2.57;
95% CI - 1.02-6.46) than those with normal 6-SMT excretion
profile.
Reduced production of melatonin in OA patients was ac-
companied with deepening the clinical symptoms, worsening
the quality of life, and depressive changes in the psycho-
emotional state. Correlation analysis confirmed that 6-SMT
excretion in OA patients was strongly associated with the total
WOMAC index (r = -0.28; p<0.01), Epworth scale (r = -0.25;
p <0.01), but a more close association was observed with
sleep disturbances (r = 0.36; p <0.001). It‘s worthy to note
that the group of patients with marginally low 6-SMT excre-
tion statistically significantly differed from the groups with
normal and low 6-SMT levels only under Epworth’s sleep and
daytime sleep profiles, while differences in clinical symptoms
of gonarthrosis (under Lequesne, WOMAC, and KOOS in-
dices) were found only in the event of a significant deficiency
of melatonin in OA patients.
3. Discussion
The data we received on inhibition of melatonin production
in OA patients and association of low 6-SMT excretion with
sleep disorders and psycho-emotional disorders are consistent
with the results of other studies. We observed a decrease
in the level of urinary melatonin in female patients with pri-
mary OA and clinical depression [2]. In the MrOS Sleep
Study, the reduction in 6-SMT excretion was closely associ-
ated with elevated daytime sleepiness, decreased effectiveness,
and reduced sleep time in elderly male subjects [7]. Hypome-
latoninemia was associated with increased depression, emo-
tional lability, aggressiveness, and neuroticism in women with
the endometrium pathology [4]. A nocturnal decrease in the
blood melatonin in patients with fibromyalgia was associated
with more pronounced night sleep disorders [3]. According
to our research, the deficiency of melatonin was also asso-
ciated with an increase in the severity of clinical symptoms,
decreased functional performance, and deterioration in the
quality of life of knee joint OA patients.
4. Prospects for further research in the
subject field
Mechanisms, through which the negative influence of mela-
tonin deficiency on the clinical course of OA may carry into
effect, need further study. The study of association of mela-
tonin production disturbance with markers of destruction and
remodeling of articular tissues in OA patients is a promising
field for further research.
5. Conclusions
1. 66% of patients with OA of knee joints manifested aber-
rant levels of 6-SMT urinary excretion, including 36.2%
of subjects with low indexes (<13.7 ng/mg creatinine).
Poorer 6-SMT excretion was associated with more pro-
nounced insomnia, Epworth’s daily drowsiness, and
Beck Depression Inventory depression (OR - 7.8; 2.68;
2.57).
2. OA patients with a 6-SMT low-excretion (<13.7 ng/mg
creatinine) presented with an increase in clinical sever-
ity of the disease, deterioration of physical functions,
and a decrease in the quality of life by Lequesne, WOMAC,
KOOS, and HAQ indexes compared to patients with
normal 6-SMT excretion. We established a statistically
reliable inverse relationship between the 6-SMT level
and the total WOMAC index (r = -0.28). OA patients
with aberrant 6-SMT levels had twice as high (OR -
2.13) chances of an increase in total WOMAC > 50
points compared to patients with normal 6-SMT excre-
tion.
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